The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...

Biotech giant Regeneron Pharmaceuticals (NASDAQ: REGN) saw its fortunes reversed last year. Regeneron's issues in the past ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

In addition to AVT06, which is a biosimilar candidate for Eylea ® (aflibercept) 2 mg, Alvotech is currently also developing AVT29, a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg.

Then, on October 31, 2024, before the market opened, Regeneron released its third quarter 2024 financial results, revealing lagging U.S. net sales for Eylea HD and Eylea. The Company reported ...

As a result, the DOJ alleges that the ASP of Regeneron's Eylea drug was inflated, which inappropriately increased Medicare reimbursements. By reimbursing credit card fees, Regeneron subsidized the ...

The fix: both GMC Sierra 1500 and GMC Sierra HD units with the incorrect or incomplete label should have a new VECI label installed by dealership service. The original label should be fully ...

This development has created uncertainty around Eylea’s future market share and pricing power. 2. Transition to Eylea HD: In response to competitive pressures, Regeneron is actively working to ...

2. Transition to Eylea HD: In response to competitive pressures, Regeneron is actively working to transition patients to Eylea HD, a higher-dose formulation. This strategy aims to maintain market ...

Highlighting the source of the food as animal- or plant-based on carbon labels makes a big difference to consumer choices. In our latest research, we show this new carbon label encourages ...

the DOJ alleges that the Average Sales Price ("ASP") for Regeneron's Eylea and Eylea HD products was inflated, which inappropriately increased Medicare reimbursements. By reimbursing credit card ...